Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels.

Autor: Hüttemann E; Internal Medicine III, University Hospital Augsburg, 86156 Augsburg, Germany.; Internal Medicine, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland., Muzalyova A; Internal Medicine III, University Hospital Augsburg, 86156 Augsburg, Germany., Gröhl K; Internal Medicine III, University Hospital Augsburg, 86156 Augsburg, Germany., Nagl S; Internal Medicine III, University Hospital Augsburg, 86156 Augsburg, Germany., Fleischmann C; Internal Medicine III, University Hospital Augsburg, 86156 Augsburg, Germany.; Department of Gastroenterology, Hepatology and Endocrinology, Klinikum Nürnberg, 90419 Nuremberg, Germany., Ebigbo A; Internal Medicine III, University Hospital Augsburg, 86156 Augsburg, Germany., Classen J; Internal Medicine III, University Hospital Augsburg, 86156 Augsburg, Germany., Wanzl J; Internal Medicine III, University Hospital Augsburg, 86156 Augsburg, Germany., Prinz F; Internal Medicine III, University Hospital Augsburg, 86156 Augsburg, Germany., Mayr P; Internal Medicine II, University Hospital Augsburg, 86156 Augsburg, Germany.; Department of Oncology and Hematology, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland., Schnoy E; Internal Medicine III, University Hospital Augsburg, 86156 Augsburg, Germany.

Publikováno v: Journal of clinical medicine [J Clin Med] 2023 Dec 27; Vol. 13 (1). Date of Electronic Publication: 2023 Dec 27.